Key Takeaways
- Sharp sequential recovery, tariff overhang lifts: Revenue rebounded +16% QoQ as US order book moved into execution and tariff-related uncertainty diluted significantly; management called the last six months "a pinch of uncertainty" but now sees clarity.
- UK is a margin story, not a growth story: Three new MHRA approvals landed, but management flagged they are "not so much topline drivers" and more bottom-line drivers, while pricing pressure persists.
- Zero-observation FDA clearance de-risks the second plant: Unit 2 at Verna, Goa passed a US FDA inspection with no Form 483, strengthening the foundation for US growth and allowing approvals from the new plant expected in '26.
- Margins guided to 19–20% for FY26: H1 EBITDA margin fell to 18.2% on employee costs from the Goa acquisition; operating leverage and cost efficiencies drove a 44% QoQ EBITDA jump, but full-year margin expansion is capped by geography-build investments.
- What to watch next quarter: Whether Q3 seasonal strength delivers the promised sequential improvement in the UK, the pace of working-capital normalization from 150 days toward 120–130 days, and any concrete M&A signings in Europe.
US Business: Tariff Clarity Unlocks the Playbook
- Tariff uncertainty has largely passed: The current US administration made clear pharma tariffs will not be imposed and even the sector investigation will not pursue pharmaceutical tariffs; clarity emerged in the last one and a half months after a period of extreme uncertainty when India was hit with 50% tariffs. Talks offers are now being introduced and a trade deal is likely.
- Growth engine restarted: Robust performance in Q2 despite micro headwinds, with a strong order book moving into execution; new launches in digestive health and pain management helped meaningful traction. Price erosion for Rx products remains in low single digits.
- Two-plant setup de-risks production: The Teva USFDA approval strengthens the foundation; having two plants allows production flexibility, and new accounts are being discussed more proactively now that clarity has emerged. Approvals from the new plant are expected in '26.
- Capacity investment returns to India: The tariff uncertainty had made the company pause on whether to invest in India or the US; with clarity, it is back to the original plan of investing in low-cost Indian manufacturing infrastructure and will not expand capacity or add a new facility in the US.
- Private-label positioning: Marksans is among the top four US players but far from the leader Perrigo, which has 50 years of presence; Marksans leverages India-based low-cost manufacturing while Perrigo is predominantly a US manufacturer, giving each different strengths.
Mark Saldanha: "I know last six months has been with a pinch of uncertainty. But now with clarity emerging, I think we will be back on track to hit our objectives. We are still targeting 30 crore in a three years."
UK & Europe: Building the Next Leg
- UK recovery on track after a one-off Q1: Q1 was soft for seasonal, global-uncertainty and geopolitical reasons; Q2 is back on schedule, Q3 will be better than Q2, and the foundation is getting stronger. New higher-value product launches are expected to have meaningful impact in the second half of calendar 2026.
- UK approvals are margin levers: Three new marketing authorizations from UK MHRA received during the quarter are "not so much topline drivers, but more bottom-line drivers," suggesting they carry better profitability than the existing mix.
- Goal to double UK revenues over 5–7 years remains firmly on track.
- Germany entry going organic: The company decided to enter the German market through the organic route; office setup is in progress and employees are being hired, with full flow expected in Q1 FY26 and results visible probably in the second half of 2026.
- Europe expansion focused on four countries: Operations to start in 2026 either organically or inorganically; smaller M&As across Europe are being looked at for conclusion in '26. The company has already taken a 100% stake to increase exposure to Dubai.
- Canada launch by 2026 adds another geography to the pipeline.
Mark Saldanha: "These approvals are not so much topline drivers, but they are more bottom-line drivers."
Margins: Operating Leverage vs. Build-Out Costs
- Gross margin declined to 57.2% from 59.7% last year, primarily reflecting product mix and pricing pressure in the UK.
- H1 EBITDA margin fell to 18.2% from 21.4% in H1 FY25, primarily due to higher employee expenses from headcount additions at the acquired Goa facility.
- QoQ profitability surged: EBITDA and PAT grew 44% and 70% sequentially respectively, supported by operating leverage and improved cost efficiencies as revenue recovered from a soft Q1.
- Full-year FY26 margins expected to settle at 19–20%, "may be slightly better." Operating leverage will improve as the company grows, but expansion into new geographies (Germany, Europe, Canada) and new infrastructure will temporarily push costs up until leverage kicks in; margins will grow slightly with revenue but will not double.
- Working capital improving: The 150-day level reflected a conscious inventory build-up of five to six months of stock during tariff uncertainty; the trend has already started coming down from Q1 to Q2 and should return to 120–130 days in the next two to three quarters.
Capacity & Infrastructure: Building for ₹5,000 Crore
- Current capacity makes ₹4,000 crore very achievable: The old plant has capacity of 70–80 crore tablets per month but is not fully utilized; the Teva plant is at ~30% or less utilization, providing ample capacity for 1–2 years.
- Expansion plan targets 120–130 crore tablets from the old plant by end of 2026, roughly 2.5x current capacity, with soft-gel capacity doubling or tripling. CAPEX of about ₹100 crores will be deployed somewhere in 2026.
- Beyond ₹4,000 crore needs new infrastructure: The cheapest route is expanding on existing land banks with shared infrastructure; build time is six to eight months once the decision is made, and investment will start when the company is trending toward ₹4,000 crores. Acquiring a facility or constructing new are alternatives.
- ₹5,000 crore revenue is a longer-duration target: Management initially said it will not happen in the next two to three years, then confirmed "maybe five to seven years" and that FY30 is "fair to say."
Mark Saldanha: "by just shifting capacity into these blocks, we can literally double if not triple our capacity from where we are."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| US order book target | ₹30 crore order book | In three years |
| Revenue target | ~₹3,000 crore | By next year |
| Revenue target | ₹5,000 crore | By FY30 ("fair to say") |
| UK revenue | Double UK revenues | Over the next 5–7 years |
| UK sequential improvement | Q3 better than Q2; 2026 better than 2025 | Q3 FY26 / CY2026 |
| UK higher-value launches | Meaningful impact from new product launches | Second half of calendar 2026 / Q3 FY26 |
| Germany operations | Full flow; results visible | Q1 FY26; second half of 2026 |
| Europe operations | Start in four countries, organically or inorganically | 2026 |
| Canada launch | Market entry | By 2026 |
| European M&A | Smaller M&As across Europe concluded | In '26 |
| Capacity expansion | Tablets to 120–130 crore; soft gels ~3x; ~₹100 crore CAPEX | End of 2026 / CAPEX deployed in 2026 |
| New plant US FDA approvals | Approvals from Unit 2 (Teva plant) | Expected in '26 |
| Working capital normalization | Return to 120–130 days | Next two to three quarters |
| Full-year FY26 EBITDA margin | 19–20% band; "may be slightly better" | FY26 |
| New infrastructure investment trigger | Invest when trending toward ₹4,000 crores revenue | No date; condition-based |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Operating revenue | ₹720.4 cr, +12.2% YoY vs ₹642 cr |
| US & North America revenue | ₹387 cr, +27% YoY |
| UK & EU formulation revenue | ₹245 cr |
| Australia & New Zealand revenue | ₹61.3 cr |
| Rest of world revenue | ₹26.5 cr |
| Gross margin | 57.2%, vs 59.7% last year; product mix and UK pricing pressure |
| EBITDA | ₹144.5 cr; EBITDA margin 20.1%, -108 bps YoY, +391 bps QoQ |
| Profit after tax | ₹99.1 cr, +1.4% YoY |
| EPS | ₹2.2 |
| US order book | $225–$230 million |
| Working capital cycle | 150 days, improved from Q1 as tariff disruptions eased; expected to return to 120–130 days in 2–3 quarters |
| Cash balance | ₹666.5 cr as of 30 Sep 2025; company remains debt-free |
| H1 R&D spend | ₹26.2 cr, 2% of consolidated revenue |
| H1 CAPEX | ₹73.2 cr |
| Teva plant (Unit 2) utilization | ~30% or less |
| Old Goa plant tablet capacity | 70–80 crore tablets per month; target 120–130 crore tablets by end of 2026 with ~₹100 cr CAPEX |
| FY26 EBITDA margin guidance | 19%–20%, may be slightly better |